We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 106

NDRC launches anti-trust investigation into pharmaceutical sector
  • CMS Cameron McKenna Nabarro Olswang LLP
  • China
  • June 8 2016

China’s top pricing-related anti-trust regulator, the National Development and Reform Commission (“NDRC”), has launched a new round of anti-trust


中国反垄断执法的新趋势
  • East & Concord Partners
  • China
  • November 3 2015

素有“经济宪法”之称的反垄断法是中国市场经济重要的基础性法律其为创造并维护市场竞争秩序营造公平的市场竞争环境保护消费者合法权益促进技术进步与创新等提供了重要的法律依据与保障


China imposes its first fines on foreign firms for price-fixing conduct
  • Winston & Strawn LLP
  • China
  • January 10 2013

On January 4, 2013, the National Development and Reform Commission (NDRC), China's antitrust regulator with jurisdiction to investigate and deal with


NDRC imposes high fines on two pharmaceutical companies for antitrust infringements
  • Herbert Smith Freehills LLP
  • China
  • November 16 2011

On 14 November 2011, China's National Development and Reform Commission ("NDRC") announced that it had imposed a fine of approximately RMB 7 million (USD 1.1 million) on two private pharmaceutical companies for colluding to raise the price of promethazine hydrochloride, the base ingredient for compound reserpine tablets, a hypertension medicine that treats high blood pressure.




Tong Yu
  • White & Case LLP

Amanda Yang
  • Reed Smith LLP


Paul Davies
  • Latham & Watkins LLP